Alzinova AB (publ) announced that the Company has strengthened its management team by appointing Sebastian Hansson as the new Business Development Director. In this newly created role, Sebastian will be instrumental in driving the strategic and operational work within Business Development for Alzinova. Alzinova appoints Sebastian Hansson as new Business Development Director with responsibility for the continued business development that runs parallel to the further development of the Company's drug candidates ALZ-101 and ALZ-201.

Sebastian holds a PhD in molecular biophysics and an MBA. He has 15 years of experience in drug development, CRO and GMP production of pharmaceutical compounds. Sebastian comes most recently from a position as Chief Operating Officer, COO at SWIPP.